193 results about "Angiopathy" patented technology

The invention relates to the technical field of medical data monitoring, in particular to a data monitoring system for chronic cardiovascular diseases. The system comprises a patient physiological index data flow acquisition module, a physiological index change feature vector conversion module, a physiological index feature collapse anomaly quantification module and a patient physiological index anomaly response early warning module. Different physiological index data can be collected in real time through intelligent wearable equipment, stream data fusion processing and baseline correction processing are carried out, time sequence synchronization processing and physiological feature vector conversion processing are further carried out, and real-time physiological index change feature vectors of a patient are obtained; and acquiring the physiological index data of the patient in the historical chronic cardiovascular case, performing feature collapse anomaly quantitative calculation and anomaly response processing, generating a physiological index change anomaly response signal of the patient, and acting on the intelligent wearable device to execute the corresponding patient physiological index anomaly early warning prompt work. According to the invention, comprehensive and real-time monitoring management of chronic cardiovascular disease patients can be realized.

The invention provides a health scheme recommendation method, device and equipment based on a large model and a knowledge graph. The method comprises the following steps: acquiring multi-modal data of a cardiovascular disease patient; the multi-modal data is preprocessed, and fusion of the multi-modal data is achieved through time alignment and feature alignment; features of the preprocessed multi-modal data are extracted, a multi-dimensional feature matrix is constructed, and the multi-dimensional feature matrix is identified and labeled; inputting the multi-dimensional feature matrix into a pre-constructed fusion behavior recognition model, enhancing the model performance through time sequence modeling and multi-modal fusion, realizing the recognition of psychological disorders, and obtaining a recognition result; and integrating the patient data, the recognition result and a pre-constructed psychological disorder knowledge graph, and adopting collaborative filtering, content recommendation and reinforcement learning methods to generate a personalized psychological health management scheme. Precise recognition and personalized management of the psychological disorder of the patient with the cardiovascular disease are achieved, and the psychological health level and life quality of the patient can be improved.

The invention discloses a post-stroke depression risk prediction system based on cerebral small vascular diseases and inflammatory markers, and relates to the technical field of computer-aided engineering, the post-stroke depression risk prediction system comprises: a data acquisition module acquires CSVD image data, serum inflammatory markers and clinical baseline information; the data preprocessing module processes image denoising registration, fills up marker missing values and encodes clinical information; the CSVD feature extraction module extracts image omics features and quantifies severity; the inflammation marker module calculates statistical characteristics and inflammation intensity; the multi-dimensional fusion module integrates features and eliminates redundancy; the risk prediction module is trained by using an improved attention CNN-LSTM model; the result output module visualizes risk and intervention suggestions; the model dynamic optimization module updates parameters by incremental learning. According to the method, multi-source key data are integrated, the prediction accuracy and generalization ability are improved, clinical interpretation and dynamic adaptability are achieved, early recognition of post-stroke depression is assisted, and patient prognosis is improved.

The invention discloses a cardiovascular lesion classification method and system based on data analysis, relates to the technical field of cardiovascular lesion classification, and aims to solve the problem of poor accuracy when cardiovascular lesions of patients are classified. According to the method, multi-dimensional features are extracted for images, time sequence signals and structured data, and fusion is realized through data layer clinical association screening, feature layer composite vector recombination and decision layer weight summation. The method breaks through the limitation of a single data dimension, enables a classification result to be more fit with a pathological mechanism, remarkably improves the recognition precision of complex lesions and complications, guarantees the reliability of hardware through precise configuration of equipment and multi-dimensional detection, customizes a preprocessing process according to the data type, and associates multi-source data through a patient ID and a timestamp, thereby improving the recognition precision of the complex lesions and complications. The problems that equipment is disordered and data formats are different in a traditional process are solved.

The invention provides a motion rehabilitation method, device and equipment for movement fear of a cardiovascular disease combined weak patient. The method comprises the following steps: S101, establishing different potential category influence factor models of movement fear of the cardiovascular disease combined weak patient on the basis of a potential category analysis method; s102, based on a knowledge graph technology, aggregating related evidence-based evidences of health education and exercise rehabilitation of the movement fear of the senile cardiovascular disease and weak patient, and constructing to obtain a knowledge graph-based exercise rehabilitation knowledge base of the movement fear of the senile cardiovascular disease and weak patient; s103, in combination with the potential category influence factor model and the multi-modal data of the patient, constructing a multi-modal data-based digital twinborn body of the senile cardiovascular disease combined with the dynamic terrorism of the weak patient; and S104, according to the dynamically updated digital twinborn model, performing matching from the exercise rehabilitation knowledge base according to the health target, the body condition, the real-time environment and the preference characteristics of the patient to obtain personalized health education and exercise prescription recommendation.

The invention relates to a cardiovascular disease risk assessment system and method. On the basis of fully considering the influence of dimension index information of kidney-related risk factors on the occurrence risk of cardiovascular diseases, heart and kidney metabolic indexes are integrated. And a mathematical model Fine-Gray is used for screening predictive factors by a step-by-step method. On the premise that traditional cardiovascular disease risk factors are reserved, in order to give consideration to the accuracy and easy generalization of risk assessment, prediction factors are simplified through strict calculation and derivation; the method is constructed based on a small amount of clinically ubiquitous detection index information such as age, sex, smoking or not, systolic pressure (SBP), fasting blood glucose (FBG), non-high density lipoprotein cholesterol (non-HDL-C) and estimated glomerular filtration rate (eGFR) as predictive factors. The method has the advantages of simplicity and convenience in operation, less required information and low professional requirement. Meanwhile, the risk of the outcome of various clinical cardiovascular diseases (including CVD, ASCVD and HF) can be evaluated at the same time, and the method can be suitable for various scenes such as primary medical care and clinical diagnosis and treatment.

The illustrative methods and systems facilitate one or more dynamic analyses that can characterize and identify synchronization between acquired cardiac signals and photoplethysmography signals to predict / estimate the presence, location, and / or severity of abnormal cardiovascular conditions or diseases, including, for example, but not limited to, coronary artery disease, heart failure (including but not limited to indicators of disease or condition, such as abnormal left ventricular end-diastolic pressure disease), and pulmonary hypertension. In some embodiments, statistical properties of the synchronization between the cardiac signal and the photoplethysmography signal are evaluated. In some embodiments, statistical properties of a histogram of synchronization between the cardiac signal and the photoplethysmography signal are evaluated. In some embodiments, statistical and / or geometric properties of a Poincare map of synchronization between the cardiac signal and the photoplethysmography signal are evaluated.

Disclosed are methods, systems, and a device for automated interpretation of cardiac magnetic resonance imaging. A method includes acquiring a sequence of radiographic images of a heart, including at least one of: a cine MRI, a late gadolinium enhancement, a T1 mapping, a T2 mapping, a perfusion imaging, a flow quantification, a dark blood imaging, a real-time imaging, a magnetic resonance spectroscopy, or a parametric mapping sequence. Further, the method processes the sequence of radiographic images using one or more machine learning models. Additionally, the method generates a diagnostic prediction using the machine learning models. The diagnostic prediction is a screening prediction of a cardiac anatomy, a diagnostic suggestion of a cardiovascular condition, a quantitative assessment of a cardiac function parameter, a structured radiographic report, a natural language summary, or a diagnostic rationale. A diagnostic prediction is output to an electronic system.

Disclosed are methods, systems, and a device for automated interpretation of cardiac magnetic resonance imaging. A method includes acquiring a sequence of radiographic images of a heart, including at least one of: a cine MRI, a late gadolinium enhancement, a T1 mapping, a T2 mapping, a perfusion imaging, a flow quantification, a dark blood imaging, a real-time imaging, a magnetic resonance spectroscopy, or a parametric mapping sequence. Further, the method processes the sequence of radiographic images using one or more machine learning models. Additionally, the method generates a diagnostic prediction using the machine learning models. The diagnostic prediction is a screening prediction of a cardiac anatomy, a diagnostic suggestion of a cardiovascular condition, a quantitative assessment of a cardiac function parameter, a structured radiographic report, a natural language summary, or a diagnostic rationale. A diagnostic prediction is output to an electronic system.

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of FKBP10 in diagnosis and treatment of atherosclerosis. Specifically, the invention demonstrates that FKBP10 promotes the unique effect of EndMT in vascular pathology, which is associated with increasing the phenotypes of atherosclerosis and unstable plaques. The invention proves that FKBP10 promotes membrane localization of PARP1, activates PI3K / AKT and MAPK signal pathways, induces EndMT and promotes atherosclerosis and poor prognosis of patients. Meanwhile, EndMT is inhibited by screening a small molecule drug TAK733, and a new scheme is provided for clinical treatment of atherosclerosis, so that the application has good potential practical application value.

The invention discloses a traditional Chinese medicine composition for treating chronic obstructive pulmonary disease as well as a preparation and application thereof, and belongs to the technical field of chronic obstructive pulmonary disease medicines. The traditional Chinese medicine composition consists of a qi tonifying component, a blood activating component and a phlegm reducing component, or consists of the qi tonifying component and the blood activating component, or consists of the qi tonifying component and the phlegm reducing component, wherein the qi-tonifying component is selected from any one or a combination of more of ginsenoside Rg1, ginsenoside Rb1, astragaloside and schizandrin; the blood activating component is selected from any one or combination of more of ligustrazine and ferulic acid; the phlegm reducing component is selected from any one or combination of more of glucosinolate and quercetin. The compatibility and combination of the medicines have obvious effects in the aspects of improving lung inflammatory response and inhibiting pathological remodeling of pulmonary blood vessels.

The present disclosure relates to methods of treating, preventing or managing cardiovascular and / or metabolic disorders selected from the group consisting of hypercholesteremia, dyslipidemia, hypertriglyceridemia, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes and obesity in a human subject in need thereof by administering a human FGF21 protein variant.

The invention provides an application of combination of indobufen and butylphthalide in preparation of a drug for preventing and / or treating cerebrovascular diseases, indobufen and butylphthalide are combined for use, have a synergistic effect, remarkably improve the treatment effect, can be used for preparing the drug for preventing, secondarily preventing or treating the cerebrovascular diseases, and has a wide application prospect. The medicine is especially suitable for treating cerebral apoplexy and transient ischemic attack, and can be used for prophylactically improving cerebral infarction caused by cerebral arterial thrombosis.

The invention relates to compounds of Formula (I), or pharmaceutically acceptable salts thereof; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may be useful as therapeutic and / or preventative agents to treat diseases that involve abnormal amino acid metabolism, amino acid transport and / or amino acid level, cardiovascular disorders, renal disorders, or metabolic diseases, such as phenylketonuria, NASH, NAFLD, heart failure, chronic kidney disease, and related disorders.

The invention relates to the technical field of electronic detection equipment, in particular to a traditional Chinese medicine external application device for cardiovascular diseases, which comprises a medicine bag and an application box for placing the medicine bag, the bottom of the application box is made of a flexible material and is provided with a plurality of through holes, and the top of the application box is detachably connected with a top plate; the application box is provided with a fixing assembly used for fixing the application box and an adjusting assembly used for adjusting the position of the medicine bag. The fixing assembly comprises positioning shells symmetrically and fixedly connected to the two sides of the application box. Piston plates are arranged in the positioning shells in a sliding fit mode. Adsorption holes are formed in the bottoms of the positioning shells; the sides, away from the adsorption holes, of the piston plates are fixedly connected with tying belts. The ends, away from the piston plate, of the laces penetrate through the side wall of the positioning shell and are in sliding fit with the positioning shell. And a positioning assembly for positioning the application position by utilizing airflow generated by the movement of the piston plate is arranged in each positioning shell. The device is complete in structure, and the application effect of the medicine bag can be effectively improved.

The present invention relates to the use of immunoregulatory macrophages for treating diseases that are associated with pathological changes of the blood vessels. The present invention particularly relates to the use of immunoregulatory macrophages for treating micro- and macroangiopathies of the lower limbs. The invention furthermore relates to the use of immunoregulatory macrophages for promoting tissue remodelling to facilitate wound healing. Pharmaceutical compositions for use in the recited treatments are also disclosed which comprise the immunoregulatory macrophages.

The present invention relates to compounds of formula (I), and stereoisomers, tautomers, N- oxides, and pharmaceutically acceptable salts thereof that are useful for modulating, preferably inhibiting three-prime repair exonuclease (TREX1). The present invention further relates to compounds of formula (I) for use as a medicament and to pharmaceutical compositions comprising said compounds. Further, the present invention relates to compounds of formula (I) and pharmaceutical compositions comprising said compounds for use in the treatment of cancer, such as breast, small cell lung cancer and colorectal cancer, in particular cancers with chromosomal instability, TREX1-mediated autoimmune diseases, inflammatory myocarditis, Aicardi-Goutières syndrome (AGS), familial chilblain lupus (FCL), systemic lupus erythematosus (SLE) and retinal vasculopathy with cerebral leukodystrophy (RVCL).

Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such as NAFLD, NASH, or MASH, or drug induced liver injury (DILI).

The present application relates to adrenergic receptor ADRAC2 antagonists, to novel substituted heterocyclic carboxamides, to a method for the production thereof, to the use thereof alone or in combination for the treatment and / or prophylaxis of diseases and to the use thereof for producing medicaments for the treatment and / or prophylaxis of diseases, in particular for the treatment and / or prophylaxis of dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea. Such as central and obstructive sleep apnea, snoring (primary and obstructive snoring); dysphagia; peripheral and cardiovascular conditions, including diabetic microangiopathy; and peripheral and central nervous system disorders, including neurodegenerative and neuroinflammatory disorders.

Compositions and methods of use for modulating APOE mediated signaling are provided. For example, immunomodulatory agents are provided that reduce APOE expression, ligand binding, crosslinking, APOE mediated signaling, or a combination thereof. In another embodiment, immunomodulatory agents are provided that enhance or promote APOE expression, ligand binding, crosslinking, APOE mediated signaling, or a combination thereof. Such agents can be used to modulate an immune response in a subject in need thereof, wherein the subject has a neurodegenerative disease, such as Alzheimer's disease or cerebral amyloid angiopathy.

The present application relates to novel substituted heterocyclic carboxamides, to a method for the production thereof, to the use thereof alone or in combination for the treatment and / or prophylaxis of diseases and to the use thereof for producing medicaments for the treatment and / or prophylaxis of diseases, in particular for the treatment and / or prophylaxis of dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea. Such as central and obstructive sleep apnea, snoring (primary and obstructive snoring); dysphagia; peripheral and cardiovascular conditions, including diabetic microangiopathy; and peripheral and central nervous system disorders, including neurodegenerative and neuroinflammatory disorders.

The invention relates to the technical field of cardiovascular disease health risk assessment and management, and discloses a cardiovascular patient group health assessment system based on diet and individual characteristics, which comprises a data acquisition module, an analysis and prediction module and a health assessment module. According to the cardiovascular patient group health assessment system based on diet and individual characteristics, a data acquisition module acquires a user data set, a data preprocessing unit identifies the user data set, a risk proportion unit calculates a disease risk ratio Hbfx, and a variable prediction unit calculates a disease prediction data set Fbyc; the health assessment module calculates a comprehensive influence data set Zhyx and comprehensively assesses the influence of significant variables of a user on CVD risks, analysis and assessment are more comprehensive and highly targeted, the health assessment module compares a reference data set according to the comprehensive influence data set Zhyx and judges and assesses corresponding scores, and the effect of early intervention and treatment of cardiovascular diseases is better.

The present invention relates to compounds of formula 1: # imgabs0 # and their use as STING antagonists, for example, the composition is used for treating diseases selected from the group consisting of systemic lupus erythematosus (SLE), (single and double gene) interferon diseases (including STING-related vascular disease (SAVI), Aicardi-Goutires syndrome (AGS), COPA syndrome and familial chilblain-like lupus, DNASE2 or ATAD3A gene mutated type I interferon disease, age-related macular degeneration (AMD), retinopathy, glaucoma, lupus erythematosus, lupus erythematosus, lupus erythematosus, lupus erythematosus, lupus erythematosus, lupus erythematosus, lupus erythematosus, lupus erythematosus, lupus erythematosus, lupus erythematosus, and lupus erythematosus. Amyotrophic lateral sclerosis (ALS), diabetes, obesity, inflammatory bowel disease (IBD), chronic obstructive pulmonary disease (COPD), Bloom syndrome, sicca syndrome, Parkinson's disease, heart failure and cancer, systemic sclerosis (SSc), dermatomyositis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), chronic plus acute liver failure (ACLF), interstitial lung disease (ILD), idiopathic pulmonary fibrosis (IPF), and the like. , aging / muscle disease, sepsis, heart failure, rheumatoid arthritis, and osteoarthritis.

This invention relates to a method and system for cardiovascular disease risk assessment based on machine learning models. By utilizing machine learning models to focus on predicting the risk of heart failure, it accurately distinguishes between healthy individuals and those with cardiovascular disease, emphasizing the differentiation of heart failure and other common cardiovascular diseases, and deeply exploring diagnostic indicators, thus opening new avenues for cardiovascular diagnosis and treatment. It hierarchically utilizes features closely related to blood cells, blood lipids, and blood glucose, and constructs predictive models using multiple machine learning models, laying a solid foundation for further in-depth research. This invention fully utilizes diagnostic indicators and multiple machine learning models, making full use of the predictive results and differentiated characteristics of different machine learning models to achieve efficient and accurate 5-category risk assessment.

Disclosed are novel compounds that are antagonists of the human GPR39 protein. Disclosed are pharmaceutical compositions of antagonists of the human GPR39 protein and methods of use. In particular, disclosed herein are methods of using the antagonists to treat diseases or conditions, including cardiovascular conditions, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, blood disorders, neurological disorders, and respiratory diseases.

The invention relates to a traditional Chinese medicine composition for treating portal vein and hepatic sinus vascular diseases. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 13-17 parts of astragalus membranaceus, 13-17 parts of angelica sinensis and 4-8 parts of leech. The invention also provides application of the traditional Chinese medicine composition in preparation of medicines for treating portal vein and hepatic sinus vascular diseases. According to the invention, an SD (Sprague Dawley) rat is fed with selenium-rich diet, meanwhile, a model is made according to a chemotherapy regimen of FOLFOX intravenously injected into the tail of the rat every week, the model is made continuously for 8 weeks, a PSVD animal model is copied, the modified Chinese angelica blood replenishing decoction is fed for intervention while the model is made, and simvastatin is taken as a positive control. Results show that the modified Chinese angelica blood replenishing decoction can significantly reduce the portal vein pressure of rats and improve related expressions of liver microangiopathy. The liver index is obviously reduced, and the spleen index is improved. Liver tissue pathological reticular staining and Japanese stellate red staining show that both the liver tissue and the Japanese stellate red staining are relieved.

Methods of administering an anti-arrhythmic, such as dofetilide, to a patient in an amount effective for treating a cardiovascular condition are described. The drug can be administered intravenously for at least one hour. A loading dose of 0.1 to 12 μg / kg bodyweight over a duration of up to 60 minutes can be administered and / or a maintenance dose of 0.1 to 10 μg / kg / hr can be administered intravenously over a duration of at least 1 hour, optionally alternatively or in addition wherein the amount of the loading dose and / or the IV maintenance dose is in the range of about ±50% of a maintenance dofetilide dose. The cardiovascular condition can include atrial fibrillation or flutter, ventricular tachycardia, hemodynamically stable or unstable ventricular tachycardia, paroxysmal atrial fibrillation, ventricular fibrillation, paroxysmal supraventricular tachycardia, heart failure, coronary artery disease, or pulmonary artery hypertension. A patient's QT interval and / or a creatinine clearance can be measured, and the effective amount can be selected based on either or both of the QT interval or the creatinine clearance measurements.

The invention relates to the technical field of medical instruments, in particular to a fixing puncture clamp for cardiovascular patients, which comprises a main body, a hemostasis pressing component is arranged at the top of the main body, and a puncture adjusting component is fixedly connected to the top of the main body; the second clamp can be controlled to slide in the sliding groove through stretching and retracting of the first telescopic rod, then the second clamp is made to be close to the first clamp, the puncture part of a patient is clamped, the purpose of length adjustment according to the body type of the patient is achieved, the stability is enhanced, meanwhile, the accuracy of the puncture needle is improved, and the work efficiency is improved. The adjustable clamping device can ensure that the puncture needle is kept stable in the puncture process, the risk of displacement or slipping is reduced, the pressing block and the hemostasis piece are controlled to press downwards through stretching and retracting of the second telescopic rod, pressing hemostasis can be accurately conducted on the punctured part, and meanwhile the pressing force can be adjusted according to needs to effectively stop hemostasis.

The invention discloses a nattokinase product for preventing and / or treating atherosclerosis and application of the nattokinase product. Cardiovascular diseases become the primary reason of human death, and the vascular plaque problem caused by atherosclerosis is always a difficult problem to be solved urgently. Blood vessel stenosis caused by plaques is a main cause of cerebral arterial thrombosis, and traditional medicines and operations face the problems of low compliance, side effect risk, indication limitation and the like. The invention provides nattokinase or a product thereof for high-risk groups with cardiovascular diseases, and the nattokinase or the product thereof is preferably in a non-drug form. As a precise nutrition intervention means, nattokinase is effective in plaque progress inhibition, unique in effect, safe to eat, convenient, easy to implement and wide in applicable crowd. The invention provides a new thought and method for management of vascular plaques and prevention and treatment of cardiovascular diseases.

The present invention relates to the technical field of limb function exercise, in particular to a limb function exercise device for use after elderly vascular diseases, including a bottom plate, one end of the top surface of the bottom plate is fixedly provided with a seat cushion, and it is characterized in that: two sliding grooves are opened at the other end of the top surface of the bottom plate, a sliding plate is arranged above the two sliding grooves, both sides of the two sliding plates are slidably connected with guide rails, guide grooves are opened on the guide rails, and all the guide rails are fixedly connected with the top of the bottom plate; a pedal is hinged on the top surface of the sliding plate, and a first torsion spring is sleeved on the hinge shaft of the pedal and the sliding plate; during the process that a vascular disease patient pushes the pedal to move to the side away from the seat cushion, relative movement occurs between the lower leg of the vascular disease patient and the extrusion rod, so that the extrusion rod can push the blood accumulated in the veins on both sides of the lower leg of the vascular disease patient to flow back towards the thigh direction, emptying the veins. By reversely pushing the blood on both sides of the lower leg of the vascular disease patient, it is beneficial to dredge the meridians of the lower leg, promote blood circulation, and play a role in promoting blood circulation and removing blood stasis.